These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission. Stein AS; O'Donnell MR; Chai A; Schmidt GM; Nademanee A; Parker PM; Smith EP; Snyder DS; Molina A; Stepan DE; Spielberger R; Somlo G; Margolin KA; Vora N; Lipsett J; Lee J; Niland J; Forman SJ J Clin Oncol; 1996 Aug; 14(8):2206-16. PubMed ID: 8708709 [TBL] [Abstract][Full Text] [Related]
47. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation. Sobecks RM; Le Beau MM; Anastasi J; Williams SF Bone Marrow Transplant; 1999 Jun; 23(11):1161-5. PubMed ID: 10382956 [TBL] [Abstract][Full Text] [Related]
48. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961 [TBL] [Abstract][Full Text] [Related]
49. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Caballero MD; Rubio V; Rifon J; Heras I; García-Sanz R; Vázquez L; Vidriales B; del Cañizo MC; Corral M; Gonzalez M; León A; Jean-Paul E; Rocha E; Moraleda JM; San Miguel JF Bone Marrow Transplant; 1997 Sep; 20(6):451-8. PubMed ID: 9313877 [TBL] [Abstract][Full Text] [Related]
50. Dose-escalated total body irradiation and autologous stem cell transplantation for refractory hematologic malignancy. McAfee SL; Powell SN; Colby C; Spitzer TR Int J Radiat Oncol Biol Phys; 2002 May; 53(1):151-6. PubMed ID: 12007954 [TBL] [Abstract][Full Text] [Related]
51. Thoracic radiation therapy before autologous bone marrow transplantation in relapsed or refractory Hodgkin's disease. PMH Lymphoma Group, and the Toronto Autologous BMT Group. Tsang RW; Gospodarowicz MK; Sutcliffe SB; Crump M; Keating A Eur J Cancer; 1999 Jan; 35(1):73-8. PubMed ID: 10211091 [TBL] [Abstract][Full Text] [Related]
53. Interstitial pneumonitis following autologous bone-marrow transplantation conditioned with cyclophosphamide and total-body irradiation. Ozsahin M; Belkacémi Y; Pène F; Laporte J; Rio B; Leblond V; Korbas D; Touboul E; Gorin NC; Schlienger M; Laugier A Int J Radiat Oncol Biol Phys; 1996 Jan; 34(1):71-7. PubMed ID: 12118567 [TBL] [Abstract][Full Text] [Related]
54. A pilot study of autologous bone marrow transplantation followed by recombinant interleukin-2 in malignant lymphomas. Vey N; Blaise D; Tiberghien P; Attal M; Pico JL; Reiffers J; Harrousseau JL; Fiere D; Tabilio A; Gabus R; Brandely M; Maraninchi D Leuk Lymphoma; 1996 Mar; 21(1-2):107-14. PubMed ID: 8907277 [TBL] [Abstract][Full Text] [Related]
55. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Brown JR; Yeckes H; Friedberg JW; Neuberg D; Kim H; Nadler LM; Freedman AS J Clin Oncol; 2005 Apr; 23(10):2208-14. PubMed ID: 15753460 [TBL] [Abstract][Full Text] [Related]
56. Risk factors for hepatic veno-occlusive disease after bone marrow transplantation: retrospective analysis of 137 cases at a single institution. Kami M; Mori S; Tanikawa S; Akiyama H; Onozawa Y; Tanaka T; Okamoto R; Maeda Y; Sasaki T; Kaku H; Matsuura Y; Hiruma K; Sakamaki H Bone Marrow Transplant; 1997 Sep; 20(5):397-402. PubMed ID: 9339756 [TBL] [Abstract][Full Text] [Related]
57. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. Schiffman K; Buckner CD; Maziarz R; Maloney DG; Appelbaum FR; Press O; Gooley T; Holmberg L; Lilleby K; Clift R; Zuckerman N; Klarnet J; Weaver C; Chauncey T; Bensinger WI Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921 [TBL] [Abstract][Full Text] [Related]
58. Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies. Kusnierz-Glaz CR; Schlegel PG; Wong RM; Schriber JR; Chao NJ; Amylon MD; Hu WW; Negrin RS; Lee Y; Blume KG; Long GD J Clin Oncol; 1997 Jan; 15(1):18-25. PubMed ID: 8996120 [TBL] [Abstract][Full Text] [Related]
59. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience. Ulrickson M; Aldridge J; Kim HT; Hochberg EP; Hammerman P; Dube C; Attar E; Ballen KK; Dey BR; McAfee SL; Spitzer TR; Chen YB Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305 [TBL] [Abstract][Full Text] [Related]
60. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. Verdonck LF; van Putten WL; Hagenbeek A; Schouten HC; Sonneveld P; van Imhoff GW; Kluin-Nelemans HC; Raemaekers JM; van Oers RH; Haak HL N Engl J Med; 1995 Apr; 332(16):1045-51. PubMed ID: 7898521 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]